摘要:
The present invention relates to the use of compounds of the general Formula (XIII): wherein A7 is C═O, C═S, SO2, CH—OR13, C═NR12, or CH2—CHOR13; A8 is C(R14)2, O, S, or NR12; A9 is C═O, C═S, SO2, CH—OR13, C═NR12,or CH2—CHOR13; m is 0, or 1 q is 0, or 1 r is 0, or 1 R12 is H, CH3, CH2—CH3, C6H5, OCH3, OCH2—CH3, OH, or SH; R13 is H, CH3, or CH2—CH3; R14 is H, alkyl, alkoxy, OH, or SH.
摘要翻译:本发明涉及通式(XIII)化合物的用途:其中A 7为CO,CS,SO 2,CH-OR 13, C-NR 12或CH 2 -CHOR 13; A 8是C(R 14)2,O,S或NR 12; A 9是CO,CS,SO 2,CH -OR 13,C-NR 12或CH < 2> -CHOR 13< 13> m为0或1 q为0或1 r为0,或1 R 12为H,CH 3,CH 2 - CH 3,C 6 H 5,OCH 3,OCH 2,-CH 2,CH 3, 3,OH或SH; R 13是H,CH 3或CH 2 -CH 3; R 14是H,烷基,烷氧基,OH或SH。
摘要:
In a healthcare data management system having autonomous information systems for scheduling procedures on imaging modalities via a central data management system, a conflict resolution method is provided. Logic for identifying conflicting messages is provided at the data management system by comparing key information in data fields. Upon identifying a conflict, conflict resolution information is transmitted back to one of the conflicting information systems via back channel. In a preferred embodiment, a proposed new value for the conflicting data field is provided by the data management logic. The information system may either accept the recommended value or generate a new value. Loss of information in the conflicting messages is thereby avoided.
摘要:
The present invention relates to the use of compounds of the general Formula (XIII): In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of microbial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.
摘要:
The present invention relates to the use of compounds of the general Formula (XIII): In particular the invention refers to a family of compounds that block the quorum sensing system of Gram-negative bacteria, a process for their manufacture, pharmaceutical compositions containing them and to their use for the treatment and prevention of microbial damages and diseases, in particular for diseases where there is an advantage in inhibiting quorum sensing regulated phenotypes of pathogens.
摘要:
The present invention relates to a phase-locked loop for frequency synthesis, which has a memory for a control value for the controllable oscillator of the phase-locked loop, which is connectable via a first switch to the control input of the controllable oscillator and is implemented to output a stored control value, and whose frequency divider is connectable at its output via a second switch to the reference oscillator.
摘要:
Apparatus for the transmission of at least first data from an electronic device (1; 1′), in particular an electromedical implant such as a cardiac pacemaker, to a monitoring arrangement (38), including at least a first interface device (6; 6′), with at least one input unit for the first data, a control device (5) connected to the first interface device (6; 6′) and a mobile radio device (7) connected to the control device at least for the transmission of the first data to the monitoring arrangement (38) by way of a telecommunication network which is at least in part in the form of a mobile radio network, wherein there is provided at least one second interface device (8) connected to the control device (5) for connecting the control device to a fixed-line telecommunication network.
摘要:
A method is described for monitoring a charging process of a battery, in which cell voltages of a plurality of battery cells are measured at regular time intervals, and loading of the battery by a process of switching on an additional electrical load is prevented if the measured cell voltage of one battery cell exceeds a predetermined cell voltage threshold value. A motor vehicle is also described, which is configured to carry out the method according to the disclosure during a battery charging process. In addition, a battery system is described, in which a controller is configured to determine an estimated value as a function of measured battery parameters during a charging process of the battery. The estimated value corresponds to the maximum temperature in the battery if the charging process is continued without interruption.
摘要:
A battery system includes a plurality of battery cells and a battery management unit. The battery management unit comprises a plurality of acquisition devices and a plurality of monitoring devices. Each of the acquisition devices is configured to acquire at least one operating parameter of the battery cells associated therewith. Each of the monitoring devices is associated with a plurality of battery cells, and each of the monitoring devices is configured to monitor the operating parameter of the battery cells associated therewith. The battery cells, which are each associated with one of the monitoring devices, are associated with at least two acquisition devices.
摘要:
The invention relates to a valve (10, 40, 60, 80, 100, 120, 150, 210), comprising a first valve element (12, 42, 62, 82, 102, 122, 152, 212) and a second valve element (14, 44, 64, 84, 104, 124, 154, 214), wherein the first valve element comprises a first carrier part (13, 43, 63, 83, 103, 123, 153, 213) which is made of plastic material and a first surface element (16, 46, 66, 86, 106, 126, 158) which is made of silicon or silicon oxide and is fastened to the first carrier part, and the second valve element comprises a second carrier part (15, 45, 65, 85, 105, 125, 155, 215) made of plastic material and a second surface element (18, 47, 67, 87, 107, 127, 159, 218) which is made of silicon or silicon oxide and is fastened to the second carrier part. The valve elements are arranged such that the first and second surface elements are seated in a planar manner against each other at least partially along an abutment surface, wherein the valve elements can be moved relative to each other in at least one direction parallel to the abutment surface of the surface elements. The first surface element has at least one first opening (20, 20′, 50, 70, 70′, 90, 90′, 110, 130, 130′, 162) and the second surface element has at least one second opening (22, 22′, 52, 52′, 52″, 72, 72′, 92, 92′, 112, 112′, 132, 132′, 163, 222), wherein the valve elements can be moved relative to each other in the at least one direction parallel to the abutment surface in at least one first position, in which the at least one first opening and the at least one second opening are in fluid connection with each other, and at least one second position, in which the at least one first opening and the at least one second opening are not in fluid connection with each other. The invention further relates to a device (200) comprising such a valve, to a use of the valve in a device, and to a micropump (400, 900), a nebulizer system (700) and a dosing/mixing device (500) comprising such a valve.
摘要:
The object of the present invention is to provide a compound having a glucokinase-activating effect.A pharmaceutical composition comprising a compound represented by the general formula (I) or a pharmaceutically acceptable salt thereof as an active ingredient: wherein X means a nitrogen atom or CR6, wherein R6 means a hydrogen atom or a halogen atom; R1 means a hydrogen atom, a C1-C6 alkyl group, a C1-C6 alkoxy group or a C1-C6 alkylthio group; R2 means a hydrogen atom or a fluorine atom; R3 means a hydrogen atom or a C1-C6 alkyl group; and one of R4 and R5 means a hydrogen atom or a C1-C6 alkyl group, and the other means a C1-C6 alkylenecarboxylic acid, a C1-C6 alkylsulfonyl group, a C1-C6 alkylcarbonyl group, or CONH2.